Harry Menon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Harry Menon has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Ali A. Mohamed
Division of Hematology-Oncology, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Penn State Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
1 shared publication - Irina V. Pinchuk
Division of Gastroenterology and Hepatology, Department of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA
1 shared publication - Marina Chulkina
Ministry of Health of the Russian Federation
1 shared publication - Nelson S. Yee
Division of Hematology & Oncology, Department of Internal Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, United States
1 shared publication
Latest Publications
- Open Access
- 5 March 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (3) , 259
Drug–Microbiota Interaction in Colon Cancer Therapy: Impact of Antibiotics
Colon adenocarcinoma is one of the most common malignancies, and it is highly lethal. Chemotherapy plays an important role in the treatment of colon cancer at various stages of the disease. The gut microbiome has emerged as a key player in colon cancer development and progression, and it can also alter the therapeutic agent’s efficacy and toxicities. Antibiotics can directly and/or indirectly affect the balance of the gut microbiome and, therefore, the clinical outcomes. In this article, we provided an overview of the composition of the gut microbiome under homeostasis and the mechanistic links between gut microbiota and colon cancer. The relationship between the use of oral antibiotics and colon cancer, as well as the impact of the gut microbiome on the efficacy and toxicities of chemotherapy in colon cancer, are discussed. Potential interventions to modulate microbiota and improve chemotherapy outcomes are discussed. Further studies are indicated to address these key gaps in the field and provide a scientific basis for the design of novel microbiota-based approaches for prevention/use as adjuvant therapeutics for patients with colon cancer.
- 5 March 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (3) , 259
Open AccessDrug–Microbiota Interaction in Colon Cancer Therapy: Impact of Antibiotics
Colon adenocarcinoma is one of the most common malignancies, and it is highly lethal. Chemotherapy plays an important role in the treatment of colon cancer at various stages of the disease. The gut microbiome has emerged as a key player in colon cancer development and progression, and it can also alter the therapeutic agent’s efficacy and toxicities. Antibiotics can directly and/or indirectly affect the balance of the gut microbiome and, therefore, the clinical outcomes. In this article, we provided an overview of the composition of the gut microbiome under homeostasis and the mechanistic links between gut microbiota and colon cancer. The relationship between the use of oral antibiotics and colon cancer, as well as the impact of the gut microbiome on the efficacy and toxicities of chemotherapy in colon cancer, are discussed. Potential interventions to modulate microbiota and improve chemotherapy outcomes are discussed. Further studies are indicated to address these key gaps in the field and provide a scientific basis for the design of novel microbiota-based approaches for prevention/use as adjuvant therapeutics for patients with colon cancer.